Safe Medication Administration — GCC Nursing Guide

The 10 Rights of Medication Administration

The rights framework is the nurse's primary safeguard against medication error. Each right must be verified independently before every administration.

10 Rights Checklist — Expand for full detail ▶

Right Patient
Use 2 independent identifiers. Acceptable: full name + date of birth, or full name + MRN. NEVER room number or bed number alone.

Right Drug
Verify generic and brand name. Check LASA pairs. Read label three times: on selection, on preparation, before administration.

Right Dose
Calculate independently. Double-check high-alert drugs with a second RN. Verify weight-based dosing.

Right Route
Confirm route on prescription. Never assume. IV drugs must never be given IM/SC unless reformulated.

Right Time
Administer within ±30 min (60 min for non-time-critical). Note Ramadan schedule adjustments for twice-daily drugs.

Right Documentation
Sign the MAR immediately after administration — never before. Never sign for another nurse. Omissions must be documented with reason code.

Right Reason
Understand the clinical indication. If the indication is unclear, clarify with the prescriber before giving.

Right Response
Assess therapeutic effect and adverse effects after administration. Document response, especially for PRN medications.

Right Refusal
Patients have the right to refuse. Document the refusal, educate the patient, notify the prescriber. Never coerce.

Right Education
Inform the patient about the drug name, purpose, common side effects, and what to report. Use patient-appropriate language.

Patient Identification

Acceptable 2-Identifier Combinations

Full legal name + Date of birth
Full legal name + Medical Record Number (MRN)
Full legal name + National ID (in GCC jurisdictions)

Always ask the patient to state their name — do not read it aloud and ask them to confirm.

Never Acceptable as Identifiers

Room number or bay letter
Bed number
Diagnosis or procedure
Physical description

Room/bed identifiers are dynamic and frequently change — their use has caused serious wrong-patient medication errors.

Allergy Verification

Allergy check is mandatory before every single administration. Do not assume you checked last shift. Verify allergy status against the MAR/eMAR, armband, and direct patient questioning on every encounter.

Distinguish true allergic reaction (immune-mediated) from intolerance/side-effect
Document nature of reaction: rash, anaphylaxis, GI intolerance, etc.
Cross-reactivity awareness: penicillin ↔ cephalosporins (~1–2% cross-reactivity), sulphonamides, NSAIDs
If patient reports new allergy: document, notify prescriber, update eMAR immediately

MAR Documentation Rules

Correct Practice

Sign/initial MAR immediately after administration
Include time of administration
Document site for injections
Document response for PRN medications
Record held doses with reason code
Late entries: label clearly as late entry with actual time

Never Do

Sign the MAR before giving the drug
Sign on behalf of another nurse
Leave blank spaces — use designated omission code
Use correction fluid (Tipp-Ex) — single line through error, initial and date
Document from memory — if in doubt, check primary source

High-Alert Medications — Double-Check Policy

ISMP High-Alert Medications Double-Check Protocol ▶

ISMP defines high-alert medications as drugs that bear a heightened risk of causing significant patient harm when used in error. Independent double-checks are required.

HIGH ALERT

Insulin

All formulations. Double-check with second RN: drug name, type (rapid/long), dose in units, route, patient identity.

HIGH ALERT

Anticoagulants

Heparin infusions, LMWH, warfarin, DOACs. Verify dose, weight-based calculations, and relevant monitoring (aPTT/INR/anti-Xa).

HIGH ALERT

Concentrated Electrolytes

KCl >20mmol/L. Must be pharmacy-prepared. NEVER stored on general wards. Requires ECG monitoring.

HIGH ALERT

Chemotherapy

Cytotoxic agents. Pharmacy-prepared only. Dedicated lines, PPE, waste disposal protocols.

HIGH ALERT

Neuromuscular Blockers

Succinylcholine, vecuronium, rocuronium. Must be clearly segregated. Inadvertent administration = respiratory arrest.

CAUTION

Opioids

Morphine, fentanyl, hydromorphone. Verify dose, route, concentration. Naloxone must be accessible.

Independent Double-Check Steps

Nurse 1 performs calculation without sharing result with Nurse 2
Nurse 2 independently calculates — compare results
If results differ, recalculate from primary source together
Both nurses sign the MAR/double-check documentation
Neither nurse is under time pressure to agree — discrepancy = stop and clarify

Medication Reconciliation

Medication reconciliation is the formal process of creating the most accurate list of all medications a patient is taking and comparing that list against prescriptions at transition points.

Admission
Compile complete home medication list (including OTC, herbal, supplements). Compare to admission orders. Clarify discrepancies with prescriber.

Transfer
Review all medications when moving between wards/units. Ensure infusions are rechecked against new orders. High-alert drugs require verification.

Discharge
Provide reconciled medication list to patient. Educate on changes, new drugs, stopped drugs. Arrange follow-up monitoring (INR, TDM, etc.).

Routes of Administration & Techniques

Oral Administration

General Principles

Position patient upright (30–90°) to prevent aspiration
Swallowing assessment for neurological/post-stroke patients
Offer full glass of water (150–200 mL) unless restricted
Remain with patient until medication swallowed
Never leave medications unattended at bedside

Tablet Crushing — NEVER Crush

Modified-release (MR/SR/XL/CR/LA) — crushing bypasses controlled release, risking overdose
Enteric-coated (EC) — crushing destroys acid protection, reduces efficacy or causes gastric harm
Sublingual/buccal tablets — designed for mucosal absorption
Cytotoxic tablets — crushing risks staff exposure

Always check a current "Do Not Crush" list or consult pharmacist before crushing any tablet.

PEG/NG Tube Administration

Key protocol: Flush → Administer → Flush

Flush with 30 mL sterile water before first drug
Flush with 10–15 mL between each drug (avoid mixing)
Flush with 30 mL after last drug
Administer each drug separately — never mix in one syringe unless specifically approved

Drug-Feed Interactions Requiring Feed Hold

Drug	Interaction	Required Hold
Phenytoin	Enteral feed reduces absorption by up to 70%	Stop feed 2 hours before and 2 hours after dose
Ciprofloxacin	Divalent cations in feed chelate fluoroquinolone	Stop feed 1–2 hours before and after dose
Warfarin	Vitamin K content in feeds may reduce anticoagulant effect	Consistent feeding schedule; monitor INR closely

Subcutaneous Injection

Insulin SC Technique

Needle length: 4–6 mm preferred for most adults
Injection angle: 90° for 4–6 mm needles (45° only if very thin, longer needle)
Sites: abdomen (fastest), thigh, upper arm, buttock
Pinch skin if using needle >6 mm or lean patient
Release pinch before withdrawing needle
Do not aspirate for SC injections
Apply gentle pressure — do not rub (affects absorption rate)

Rotation Protocol

Rotate injection sites systematically to prevent lipohypertrophy (hardened fatty tissue = erratic insulin absorption). Document site used on MAR. Use rotation chart: divide abdomen into quadrants, rotate clockwise, space each injection 2–3 cm apart within zone.

Injecting into lipohypertrophic tissue causes unpredictable glucose control — inspect sites regularly.

Intramuscular Injection

Site	Max Volume	Preferred Use	Notes
Ventrogluteal	3–5 mL	Adults — preferred IM site	Away from major nerves/vessels; large muscle mass
Deltoid	1–2 mL	Vaccines, small volumes	Locate 2–3 finger-widths below acromion
Vastus Lateralis	3–5 mL adults; 1–3 mL infants	Paediatric — preferred	Outer thigh; well developed in infants
Dorsogluteal	—	NOT RECOMMENDED	Risk of sciatic nerve injury. No longer recommended in evidence-based practice.

Z-Track Technique

Draw medication into syringe; change needle after drawing up
Pull skin and subcutaneous tissue laterally 2–3 cm from injection site
Insert needle at 90° while maintaining skin displacement
Aspirate (if institutional policy requires — controversial for deltoid)
Inject slowly (10 sec/mL)
Wait 10 seconds before withdrawing
Withdraw needle; release skin displacement simultaneously
Apply gentle pressure — do NOT rub (spreads irritating medication)

Z-track seals drug in muscle, preventing leakage into subcutaneous tissue. Required for iron (Cosmofer), hydroxyzine, certain vaccines.

Intravenous Administration

IV Bolus

Confirm IV cannula patency by flushing with 10 mL 0.9% NaCl first
Administer at prescribed rate — avoid rapid push unless emergency
Flush after with 10 mL 0.9% NaCl
Observe for signs of extravasation: swelling, pain, blanching
Compatibility check before co-administration through same line

IV Infusion

Check compatibility of drug with diluent and infusion bag
Label infusion bag: drug, dose, concentration, rate, time started, expiry, nurse initials
Use infusion pump for hazardous drugs — never free-flow
Change infusion sets per policy (typically 72–96 h; lipid/blood products 24 h)
Check for precipitate, colour change, cloudiness before hanging

Topical & Transdermal

Transdermal Patches

Remove previous patch before applying new one
Document removal and application site on MAR
Apply to clean, dry, hairless skin (upper arm, chest, back)
Rotate sites to prevent skin sensitisation
Do not cut patches — alters release kinetics
Used patches still contain drug — fold sticky side in before disposal

Skin Assessment

Inspect site before applying: no broken skin, dermatitis, oedema
Document any skin reactions at previous site
Fentanyl patches: heat sources (heating pad, fever) increase absorption — monitor for toxicity
GTN patches: medication-free interval (8–12 h) to prevent tolerance

High-Alert Medications — Detailed Reference

ISMP High-Alert Medications require special safeguards, heightened awareness, and independent double-checks. Errors with these drugs are more likely to cause significant harm or death.

Concentrated Electrolytes

Potassium Chloride (KCl) — Critical Rules

NEVER store concentrated KCl on general wards. Concentrated KCl ampoules must be held in pharmacy only. Inadvertent IV bolus of KCl = cardiac arrest.

All IV potassium must be pharmacy-prepared in premixed bags
Maximum concentration peripheral: ≤20 mmol/L (or per local policy, typically 40 mmol/L in 1L bag)
Maximum rate peripheral: <10 mmol/hr
Central line only if rate >20 mmol/hr or concentration >40 mmol/L

Monitoring Requirements (IV Potassium)

Continuous ECG monitoring
Serum potassium every 4–6 hours during replacement
Urine output ≥0.5 mL/kg/hr (adequate renal function)
Watch for: peaked T waves, widened QRS, sine wave pattern (toxicity)
Target serum K+: 3.5–5.0 mmol/L

Insulin

Insulin Safety Rules

NEVER abbreviate "units" as "U" or "IU" — handwritten "U" misread as "0" has caused 10-fold overdoses. Always write the word "units" in full.

Always double-check dose with a second RN before administration
Verify insulin type: rapid-acting vs short-acting vs intermediate vs long-acting — they look similar but act very differently
Cloudy insulins (NPH, premixed) require gentle mixing — do not shake vigorously
Clear insulins should be clear — discard if cloudy

Common Insulin Types (GCC market)

Type	Example	Onset
Rapid-acting	NovoRapid, Humalog	10–20 min
Short-acting	Actrapid, Humulin R	30–60 min
Intermediate	Insulatard, Humulin N	1–3 hr
Long-acting	Lantus, Levemir	1–4 hr
Premixed	Mixtard, NovoMix	Dual peak

Anticoagulants

Heparin Infusion

Weight-based dosing: initial bolus 80 units/kg; infusion 18 units/kg/hr (per institutional protocol)
Monitor aPTT 6 hours after initiation; target typically 60–100 seconds (1.5–2.5× control)
Adjust rate per sliding scale protocol
Watch for HIT (Heparin-Induced Thrombocytopenia): platelet count falling 50% at days 5–10 = stop heparin immediately
Antidote: Protamine sulphate (1 mg neutralises 100 units heparin)

LMWH (Enoxaparin/Dalteparin)

Standard dosing: enoxaparin 1 mg/kg SC every 12 h (therapeutic)
Anti-Xa monitoring required in: renal impairment (CrCl <30 mL/min), extremes of weight (BMI >40 or <50 kg), pregnancy
Target anti-Xa: 0.5–1.0 units/mL (BD dosing), 1.0–2.0 units/mL (OD dosing)
Dose reduction or switch to unfractionated heparin if CrCl <30 mL/min
No reliable reversal agent — protamine partially reverses (~60%)

Digoxin

Digoxin — Narrow Therapeutic Index Drug

Therapeutic range: 0.8–2.0 nmol/L (some sources: 0.5–2.0 ng/mL)
Always check apical pulse for 1 full minute before giving: hold if HR <60 bpm (notify prescriber)
Check serum potassium: hypokalaemia potentiates digoxin toxicity
Narrow therapeutic index — toxic at only twice the therapeutic dose
Half-life 36–48 hours — accumulation risk in renal impairment

Signs of Digoxin Toxicity

Nausea, vomiting, anorexia (early)
Visual disturbances: yellow/green halos, blurred vision
Bradycardia, heart block, arrhythmias
ECG: Scooped ST depression ("digoxin effect"), PR prolongation

Antidote: Digoxin-specific antibody fragments (DigiFab/Digibind) — specialist use.

IV Drug Calculations

Core Formulas

Weight-Based Infusion Rate

Rate (mL/hr) = Dose × Weight(kg) × 60
─────────────────────────────
Concentration (mcg/mL or mg/mL)

Example — Dopamine: 5 mcg/kg/min for 70 kg patient; bag = 200 mg in 50 mL (concentration = 4000 mcg/mL)

Rate = 5 × 70 × 60 / 4000 = 5.25 mL/hr

Note: 200 mg/50 mL = 4 mg/mL = 4000 mcg/mL

Drops per Minute (Gravity)

Drops/min = Volume (mL) × Drop factor
──────────────────────────────
Time (minutes)

Drop factors: Macro-drip = 20 drops/mL (standard); 15 drops/mL (some sets); Micro-drip = 60 drops/mL

Example: 1000 mL over 8 hours (480 min), 20 drops/mL:

Drops/min = 1000 × 20 / 480 = 41.7 ≈ 42 drops/min

Percentage Solutions

1% solution = 10 mg per mL
0.9% NaCl = 9 mg/mL NaCl
5% glucose = 50 mg/mL glucose
50% glucose = 500 mg/mL glucose

Millimoles & Reconstitution

Millimoles = mass (mg) / molecular weight (g/mol)

KCl: MW = 74.5 g/mol
1 g KCl = 1000mg/74.5 = 13.4 mmol
10% KCl (10g/100mL) = 1.34 mmol/mL

Reconstitution: Final concentration = Drug amount / (Powder displacement volume + Diluent volume). Always check manufacturer data for displacement volume.

IV Solution Osmolarity Reference

Solution	Osmolarity	Tonicity	Main Use
0.9% Sodium Chloride (Normal Saline)	308 mOsm/L	Isotonic	Fluid resuscitation, drug diluent, electrolyte replacement
Hartmann's / Ringer's Lactate	273 mOsm/L	Slightly hypotonic	Fluid resuscitation, perioperative; preferred over NS in large volumes
5% Dextrose (D5W)	278 mOsm/L	Isotonic (becomes hypotonic after dextrose metabolised)	Drug diluent; hypoglycaemia; free water replacement
0.45% Sodium Chloride (Half-Normal Saline)	154 mOsm/L	Hypotonic	Free water replacement; chronic hypernatraemia correction
3% Sodium Chloride	1026 mOsm/L	Hypertonic	Severe symptomatic hyponatraemia — ICU use only
10% Dextrose	556 mOsm/L	Hypertonic	Parenteral nutrition additive; hypoglycaemia

GCC-Relevant Drug Infusion Examples

Morphine Infusion

Bag: 50 mg morphine in 50 mL 0.9% NaCl → 1 mg/mL

Dose: 2 mg/hr → Rate = 2 mL/hr

Dose: 0.02 mg/kg/hr for 70 kg = 1.4 mg/hr → Rate = 1.4 mL/hr

Noradrenaline Infusion

Bag: 4 mg noradrenaline in 50 mL → 80 mcg/mL

Dose: 0.1 mcg/kg/min for 70 kg:

Rate = 0.1 × 70 × 60 / 80 = 5.25 mL/hr

Amiodarone Infusion

Loading: 300 mg in 250 mL 5% dextrose over 1 hour → 300 mL/hr (infusion pump).

Maintenance: 900 mg in 500 mL 5% dextrose over 23 hours → 21.7 mL/hr

Administer via central line if possible — peripheral extravasation causes tissue necrosis. Use a filter.

Insulin Infusion (DKA Protocol)

Bag: 50 units regular insulin in 50 mL 0.9% NaCl → 1 unit/mL

Dose: 0.1 unit/kg/hr for 70 kg = 7 units/hr → Rate = 7 mL/hr

Double-check all insulin infusion rates. Monitor glucose hourly. Transition to SC insulin when DKA resolved and patient eating.

IV Infusion Rate Calculator

IV Drug Infusion Rate Calculator

Quick presets:

Drug Name

Drug Amount in Bag

Bag Volume (mL)

Patient Weight (kg)

Prescribed Dose

Dose Unit

Concentration

—

Infusion Rate

—

mL/hr

Dose Check

—

Sanity Check

—

Drug Interactions & Medication Errors

LASA Drugs — Look-Alike Sound-Alike

GCC-Relevant LASA Drug Pairs Reference ▶

Use TALL MAN lettering to differentiate LASA pairs (e.g., hydrOXYzine vs hydrALAzine). Store separately. Apply LASA warning stickers per institutional policy.

Corticosteroids

prednisolone↔prednisone↔methylprednisolone

dexamethasone↔betamethasone

Opioids

hydromorphone↔morphine FATAL

tramadol↔toradol (ketorolac)

fentanyl patch 25 mcg↔fentanyl patch 250 mcg

Cardiovascular

metoprolol↔metformin

amlodipine↔amloride (amiloride)

digoxin↔digitoxin

Antibiotics

cefazolin↔cefuroxime↔ceftriaxone

vancomycin↔gentamicin (different classes, both nephrotoxic)

Anticoagulants

heparin↔hespan (hetastarch) FATAL

enoxaparin↔dalteparin

Diabetes

Lantus (insulin glargine)↔Lente insulin

NovoRapid↔Novolin (Actraphane)

Electrolytes

KCl (Potassium Chloride)↔NaCl (Sodium Chloride) FATAL if IV KCl bolus

ISMP Do-Not-Use Abbreviations

Abbreviation	Intended Meaning	Misread As	Use Instead
U or u	Units	"0" or "4" (10U → 100)	Write "units" in full
IU	International Units	"IV" (intravenous)	Write "international units"
QD	Every day (once daily)	QID (4 times daily)	Write "daily" or "once daily"
QOD	Every other day	QD or QID	Write "every other day"
Trailing zero (1.0 mg)	1 mg	10 mg	Write "1 mg" (no trailing zero)
Naked decimal (.5 mg)	0.5 mg	5 mg (decimal missed)	Write "0.5 mg" (leading zero)
MSO4 / MS	Morphine sulphate	Magnesium sulphate	Write "morphine sulphate"
MgSO4	Magnesium sulphate	Morphine sulphate	Write "magnesium sulphate"
µg	Micrograms	mg (milligrams) — 1000× error	Write "mcg" or "micrograms"

Drug-Food Interactions

Drug	Food/Substance	Interaction	Management
Warfarin	Vitamin K-rich foods (leafy greens, broccoli)	Reduces anticoagulant effect; variable INR	Consistent intake rather than avoidance; monitor INR
Statins (simvastatin, atorvastatin)	Grapefruit / grapefruit juice	CYP3A4 inhibition → increased statin levels → myopathy/rhabdomyolysis	Avoid grapefruit; switch to pravastatin (not CYP3A4-dependent)
MAOIs (phenelzine, tranylcypromine)	Tyramine-rich foods (aged cheese, red wine, cured meats)	Hypertensive crisis	Strict tyramine-free diet; carry crisis card
Tetracyclines / Fluoroquinolones	Dairy products, antacids, iron supplements	Chelation reduces absorption	Take 2 hours before or 4 hours after divalent cations
Levodopa	High-protein meals	Amino acid competition reduces CNS absorption	Take 30–60 min before meals; consistent protein intake

Drug-Drug Interactions

Drug Combination	Mechanism	Effect	Action
NSAIDs + Anticoagulants	Additive anticoagulation + GI mucosal damage	Major bleeding risk	Avoid combination; use paracetamol for analgesia; add PPI if unavoidable
Methotrexate + NSAIDs	NSAIDs reduce renal methotrexate clearance	Methotrexate toxicity (bone marrow suppression, mucositis)	Avoid combination especially in high-dose MTX; use with extreme caution in low-dose
Statins + Azole antifungals	CYP3A4 inhibition by azoles → increased statin concentration	Myopathy, rhabdomyolysis	Hold simvastatin/lovastatin during short azole courses; dose-reduce or use non-interacting statin
ACE inhibitor + Potassium-sparing diuretic	Both increase serum K+	Life-threatening hyperkalaemia	Monitor K+ closely; avoid combination unless specifically indicated (heart failure)
Digoxin + Amiodarone	Amiodarone inhibits P-glycoprotein → increased digoxin levels	Digoxin toxicity	Reduce digoxin dose by 50% when starting amiodarone; monitor levels
Warfarin + Antibiotics (broad-spectrum)	Gut flora alteration reduces vitamin K production	Increased INR → bleeding	Increased INR monitoring; adjust warfarin dose accordingly

Medication Error Reporting

Error Classification

Near-miss (close call): Error caught before reaching patient. Must still be reported — highest learning value.
Adverse drug event (ADE): Harm caused by medication use (whether from error or not)
Adverse drug reaction (ADR): Unintended, harmful reaction at normal doses (not error)
Medication error: Any preventable event that may cause or lead to inappropriate medication use or patient harm

GCC Reporting Systems

Saudi Arabia: MOH NAPS (National Adverse event Reporting System); hospital-level CERNER incident reporting
Dubai/UAE: DHA ePMS (electronic Patient Management System) incident module; HAAD/DOH reporting systems
Qatar: MOPH/PHCC reporting frameworks; QCHP oversight

All GCC jurisdictions require near-miss reporting. Anonymous reporting encouraged to maximise safety learning.

Duty of Candour

When a medication error reaches a patient, the nurse has a professional and ethical duty to:

Ensure patient safety immediately (assess for harm, escalate)
Notify the attending physician/prescriber
Document accurately and factually in medical records
Inform the patient (and/or family) honestly and apologetically
Complete an incident report
Cooperate fully with any investigation

Swiss Cheese Model & RCA

Reason's Swiss Cheese Model: medication errors occur when multiple defensive layers (checks, policies, systems) have simultaneous holes that align. No single cause — system failure.

Root Cause Analysis (RCA): A structured method to identify contributing factors after a serious event. Focus: "why did the system fail?" not "who made the mistake?" Outputs: systemic recommendations, not individual blame. Required for serious/sentinel medication events in all GCC jurisdictions.

GCC Context — Medication Safety & Exam Preparation

GCC Medication Safety Frameworks

Saudi Arabia

Saudi MOH National Patient Safety Centre (NPSC) — oversees national medication safety initiatives, mandatory incident reporting, national patient safety goals aligned with JCI/CBAHI
CBAHI (Central Board for Accreditation of Healthcare Institutions) — standards for medication management, high-alert drug policies, double-check requirements
SCFHS (Saudi Commission for Health Specialties) — licensing and competency assessment including pharmacology for nurses
DEA-equivalent: Saudi MOH Narcotics Control Department — strict schedule control for opioids, benzodiazepines

UAE (DHA / DOH / MOH)

DHA Medication Safety Programme (Dubai) — focus on high-alert medications, LASA management, error reporting via ePMS
DOH Abu Dhabi — medication management standards, clinical governance framework
UAE National Patient Safety Framework — overarching framework harmonising all emirates
DHA/DOH Nursing Competencies — include medication administration competency assessment for license issuance and renewal

Qatar / Bahrain / Kuwait / Oman

QCHP (Qatar Council for Healthcare Practitioners) — licensing, CPD, medication safety standards
MOH Kuwait/Bahrain/Oman — aligned with GCC harmonised medication schedules
ISMP Middle East — regional adaptation of ISMP guidelines, LASA lists contextualised for GCC drug markets (Arabic brand names, locally available generics)

Controlled Drugs in GCC

All GCC states maintain strict narcotics schedules equivalent to DEA controlled substances
Opioids, benzodiazepines, barbiturates: require special controlled drug registers, dual-nurse signatures for administration, locked storage with access log
Wasting of unused portions: witnessed and documented by two nurses
Discrepancies must be reported immediately to pharmacy and line manager
Cross-border movement of controlled drugs for patients requires prior authorisation from national health authorities

Arabic Medication Labelling

In GCC facilities, medication labels are required to include Arabic language information. Key considerations:

Dual-language labels (Arabic/English) are standard in Saudi, UAE, Kuwait, Bahrain, Qatar, Oman
Nurses working in GCC must be familiar with Arabic drug names, dosing instructions, and warning labels even if not fluent in Arabic
Common Arabic medication terms: جرعة (dose), مرة في اليوم (once daily), قبل الأكل (before food), بعد الأكل (after food), حقن (injection), وريدي (intravenous)
In multi-national GCC workforce: never assume translation accuracy on patient-labelled medications brought from home — verify with pharmacist

Polypharmacy in Elderly GCC Patients

STOPP/START Criteria

STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) are validated tools for detecting potentially inappropriate prescribing in elderly patients.

Common STOPP Criteria (Drugs to Stop)

Benzodiazepines — fall risk, cognitive impairment
First-generation antihistamines — anticholinergic burden
NSAIDs with CKD or heart failure
Antipsychotics in dementia — increased mortality
Sliding-scale insulin — hypoglycaemia risk without benefit
Proton pump inhibitors at maximum dose for >8 weeks without indication

Polypharmacy Context in GCC

High prevalence of type 2 diabetes, hypertension, dyslipidaemia in elderly GCC population → complex polypharmacy regimens common
Traditional/herbal medicine use common — always ask about supplements and traditional remedies
Language barriers in non-Arabic-speaking nurses → use professional interpreter for medication counselling
Family involvement in medication management is culturally expected — include family in education

Ramadan Medication Timing

Adjusting Medications for Ramadan Fasting

Ramadan fasting (approximately 29–30 days) requires proactive medication schedule review for Muslim patients. Nurses must understand these adjustments.

Timing Principles

Twice-daily medications: shift to Suhoor (pre-dawn meal) and Iftar (sunset meal) — maintain approximately 12-hour spacing
Three-times-daily: challenging — discuss with prescriber; consider switch to extended-release once-daily formulation
Once-daily: minimal change — take at Iftar or Suhoor per drug profile
Extended-release (XL/SR) formulations preferred during Ramadan — single daily dose feasible for many drugs

High-Risk Medications in Ramadan

Insulin: fasting alters glucose dynamics; basal insulin may need dose reduction; consult diabetes team
Sulphonylureas (glibenclamide, glipizide): high hypoglycaemia risk while fasting — switch or reduce dose
Anticoagulants: dietary changes affect warfarin INR; DOAC timing adjustment needed
Antihypertensives: dehydration during long fasting days can cause hypotension — monitor BP
Diuretics: risk of dehydration/electrolyte imbalance — timing at Iftar preferred

Patients with uncontrolled diabetes, heart failure, or renal disease may be exempt from fasting under Islamic law — explore this sensitively with appropriate religious guidance if medically required.

Generic vs Brand Name in GCC Workforce

The GCC multi-national healthcare workforce creates unique risks when nurses trained in different countries use brand names that differ from locally marketed products.

Always verify generic (INN) name alongside brand name — prescriptions in GCC may use either
Saudi MOH has mandated generic prescribing in public sector — nurses must be familiar with INN names
Brand names for the same generic differ across GCC states (e.g., paracetamol = Panadol/Calpol/Tylenol/Adol)
Biosimilars are increasingly used in GCC — confirm with pharmacist before substituting any biological product
ISMP Middle East maintains a GCC-specific LASA list accounting for Arabic phonetics and regional brand names

DHA / SCFHS / QCHP Pharmacology MCQs — Exam Preparation

1. A nurse is preparing to administer IV potassium chloride 40 mmol in 1000 mL 0.9% NaCl at 10 mmol/hr. Which action is the PRIORITY before initiating this infusion?

A. Crush and dissolve the KCl tablet at the bedside if no IV preparation available

B. Confirm continuous ECG monitoring is in place and review the most recent serum potassium

C. Administer a rapid IV bolus of KCl first, then start the infusion

D. Store the KCl ampoule on the ward for quick access when needed

Correct Answer: B. IV potassium requires continuous ECG monitoring due to the risk of fatal arrhythmias. Serum K+ must be confirmed first. Option A — concentrated KCl must never be prepared on the ward; Option C — IV bolus KCl can cause cardiac arrest; Option D — concentrated KCl must never be stored on general wards (ISMP highest-alert practice).

2. A nurse is about to administer insulin and writes "10U" on the medication administration record. What is the correct action?

A. This is acceptable — "U" is a standard abbreviation for units

B. Correct the documentation to read "10 units" — "U" is on the ISMP Do-Not-Use list as it can be misread as zero, resulting in a 10-fold overdose

C. Use "IU" instead of "U" as it is more specific

D. Abbreviation is acceptable in electronic records only

Correct Answer: B. "U" and "IU" are both on the ISMP Do-Not-Use list. "U" handwritten can be misread as "0" (10U → 100) or "4" (4U → 44). The word "units" must always be written in full for insulin and any other drugs measured in units.

3. A nurse is administering phenytoin suspension via a nasogastric tube. The patient is receiving continuous enteral feed. What is the correct action regarding the feed?

A. Administer phenytoin mixed directly into the enteral feed for convenience

B. Stop the enteral feed 2 hours before and 2 hours after phenytoin administration, and flush the tube with 30 mL water before and after the dose

C. Phenytoin can be given with enteral feed without any interaction concerns

D. Crush a phenytoin tablet and mix with 10 mL water for tube administration

Correct Answer: B. Enteral feeds reduce phenytoin absorption by up to 70% through protein binding. The feed must be stopped 2 hours before and 2 hours after the dose. The tube is flushed with 30 mL water before and after. Option D — phenytoin suspension (liquid formulation) is preferred for NG/PEG tubes; tablets should not be crushed for tube use without pharmacist approval and phenytoin is available as a suspension.

4. A nurse is administering enoxaparin to a patient with chronic kidney disease (CrCl = 25 mL/min). Which monitoring parameter is MOST important?

A. aPTT (activated partial thromboplastin time)

B. Prothrombin time / INR

C. Anti-Xa level

D. Platelet count only

Correct Answer: C. Anti-Xa level is the appropriate monitoring parameter for LMWH (enoxaparin) in patients with renal impairment (CrCl <30 mL/min), extremes of weight, or pregnancy. LMWH is primarily renally cleared and accumulates in renal impairment, increasing bleeding risk. aPTT (A) is used to monitor unfractionated heparin infusions; INR (B) monitors warfarin therapy. Dose reduction or switch to unfractionated heparin is often required when CrCl <30 mL/min.

5. A Muslim patient with type 2 diabetes is planning to fast during Ramadan. They currently take glibenclamide (a sulphonylurea) twice daily. What is the nurse's BEST response?

A. Advise the patient to take both doses at Iftar to maintain control

B. Instruct the patient to stop glibenclamide completely during Ramadan

C. Inform the patient that sulphonylureas carry high hypoglycaemia risk during fasting and refer to the diabetes team for medication review before Ramadan

D. Ramadan has no effect on diabetes medications — no change needed

Correct Answer: C. Sulphonylureas (glibenclamide, glipizide) stimulate insulin secretion regardless of food intake, creating high hypoglycaemia risk during fasting periods. The nurse should not independently change or stop medications but must refer promptly to the diabetes multidisciplinary team for a Ramadan-specific medication review. Options to consider include switching to a safer agent (e.g., DPP-4 inhibitor, SGLT-2 inhibitor) or dose adjustment. This referral is best made weeks before Ramadan begins.